A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo

Diabetes

Volumn 59, Issue 12, 2010, Pages 2999-3007

  An, Zhibo ^a   Winnick, Jason J ^a   Farmer, Ben ^a   Neal, Doss ^a   Lautz, Margaret ^a   Irimia, Jose M ^b   Roach, Peter J ^b   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CARBON; CYCLIC GMP; GLUCAGON; GLUCOSE; GLYCEROL; GLYCOGEN; GUANYLATE CYCLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LACTIC ACID; NITRIC OXIDE; PHOSPHODIESTERASE III; SODIUM CHLORIDE; SOLUBLE GUANYLATE CYCLASE; SOMATOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPERIMENTAL DOG; FATTY ACID METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; HORMONE DETERMINATION; HYPERGLYCEMIA; LIVER BLOOD FLOW; LIVER METABOLISM; MALE; NET HEPATIC GLUCOSE UPTAKE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; BLOOD GLUCOSE; DOGS; FEMALE; GLUCAGON; GLUCOSE; GUANYLATE CYCLASE; HEMATOCRIT; HEPATIC VEINS; HOMEOSTASIS; INSULIN; LIVER; MALE; NITRIC OXIDE; SOMATOSTATIN;

EID: 78650073368     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0138     Document Type: Article

References (48)

1. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999;48:1198-1214
2. Adkins-Marshall BA, Myers SR, Hendrick GK, Williams PE, Triebwasser K, Floyd B, Cherrington AD. Interaction between insulin and glucose-delivery route in regulation of net hepatic glucose uptake in conscious dogs. Diabetes 1990;39:87-95
3. Myers SR, McGuinness OP, Neal DW, Cherrington AD. Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 1991;87:930-939
4. Pagliassotti MJ, Cherrington AD. Regulation of net hepatic glucose uptake in vivo. Annu Rev Physiol 1992;54:847-860
5. An Z, DiCostanzo CA, Moore MC, Edgerton DS, Dardevet DP, Neal DW, Cherrington AD. Effects of the nitric oxide donor SIN-1 on net hepatic glucose uptake in the conscious dog. Am J Physiol Endocrinol Metab 2008;294:E300-E306
6. Moore MC, DiCostanzo CA, Farmer B, Smith MS, Snead WL, Cherrington AD. Portal delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake in the conscious dog. Diabetologia 2005;48:A228
7. Ziolo MT, Kohr MJ, Wang H. Nitric oxide signaling and the regulation of myocardial function. J Mol Cell Cardiol 2008;45:625-632.
8. Stamler JS, Lamas S, Fang FC. Nitrosylation. the prototypic redox-based signaling mechanism. Cell 2001;106:675-683 (Pubitemid 32900659)
9. Ming Z, Han C, Lautt WW. Nitric oxide inhibits norepinephrine-induced hepatic vascular responses but potentiates hepatic glucose output. Can J Physiol Pharmacol 2000;78:36-44 (Pubitemid 30097348)
10. Sadri P, Lautt WW. Blockade of hepatic nitric oxide synthase causes insulin resistance. Am J Physiol 1999;277:G101-G108
11. Correia NC, Guarino MP, Raposo J, Macedo MP. Hepatic guanylyl cyclase inhibition induces HISS-dependent insulin resistance. Proc West Pharmacol Soc 2002;45:57-58
12. Galassetti P, Shiota M, Zinker BA, Wasserman DH, Cherrington AD. A negative arterial-portal venous glucose gradient decreases skeletal muscle glucose uptake. Am J Physiol 1998;275:E101-E111 (Pubitemid 128731400)
13. Morgan CR, Lazarow A. Immunoassay of insulin using a two-antibody system. Proc Soc Exp Biol Med 1962;110:29-32
14. Moore MC, Rossetti L, Pagliassotti MJ, Monahan M, Venable C, Neal D, Cherrington AD. Neural and pancreatic influences on net hepatic glucose uptake and glycogen synthesis. Am J Physiol 1996;271:E215-E222
15. Winnick JJ, An Z, Moore MC, Ramnanan CJ, Farmer B. A physiological increase in the hepatic glycogen level does not affect the response of net hepatic glucose uptake to insulin. Am J Physiol Endocrinol Metab 2009;297:E358-E366.
16. Loten EG, Francis SH, Corbin JD. Proteolytic solubilization and modification of hormone-sensitive cyclic nucleotide phosphodiesterase. J Biol Chem 1980;255:7838-7844
17. Gilboe DP, Larson KL, Nuttall FQ. Radioactive method for the assay of glycogen phosphorylases. Anal Biochem 1972;47:20-27
18. Guinovart JJ, Salavert A, Massague J, Ciudad CJ, Salsas E, Itarte E. Glycogen synthase: a new activity ratio assay expressing a high sensitivity to the phosphorylation state. FEBS Lett 1979;106:284-288
19. Leevy CM, Mendenhall CL, Lesko W, Howard MM. Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962;41:1169-1179
20. Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, Cherrington AD. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes 2002;51:1663-1671 (Pubitemid 34564276)
21. Edgerton DS, Lautz M, Scott M, Everett CA, Stettler KM, Neal DW, Chu CA, Cherrington AD. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006;116:521-527
22. Hsieh PS, Moore MC, Neal DW, Cherrington AD. Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs. Am J Physiol 1998;275:E987-E992
23. Moore MC, Hsieh PS, Flakoll PJ, Neal DW, Cherrington AD. Differential effect of amino acid infusion route on net hepatic glucose uptake in the dog. Am J Physiol 1999;276:E295-E302
24. Alexander B. The role of nitric oxide in hepatic metabolism. Nutrition 1998;14:376-390 (Pubitemid 28222237)
25. Feelisch M, Kotsonis P, Siebe J, Clement B, Schmidt HH. The soluble guanylyl cyclase inhibitor 1H-(1,2,4)oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol 1999;56:243-253
26. Wei CL, Khoo HE, Lee KH, Hon WM. Differential expression and localization of nitric oxide synthases in cirrhotic livers of bile duct-ligated rats. Nitric Oxide 2002;7:91-102
27. Borgs M, Bollen M, Keppens S, Yap SH, Stalmans W, Vanstapel F. Modulation of basal hepatic glycogenolysis by nitric oxide. Hepatology 1996;23:1564-1571 (Pubitemid 26181241)
28. Sprangers F, Sauerwein HP, Romijn JA, van Woerkom GM, Meijer AJ. Nitric oxide inhibits glycogen synthesis in isolated rat hepatocytes. Biochem J 1998;330(Pt 2):1045-1049
29. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-(1,2,4)oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 1995;48:184-188
30. Mannick JB, Miao XQ, Stamler JS. Nitric oxide inhibits Fas-induced apoptosis. J Biol Chem 1997;272:24125-24128
31. An Z, Winnick JJ, Farmer B, Lautz M, Neal D, Snead W, Cherrington AD. The cGMP pathway plays a role in the regulation of net hepatic glucose uptake (NHGU) in conscious dogs. Diabetes 2010;59:A412
32. Vaandrager AB, de Jonge HR. Signalling by cGMP-dependent protein kinases. Mol Cell Biochem 1996;157:23-30
33. Walter U. Distribution of cyclic-GMP-dependent protein kinase in various rat tissues and cell lines determined by a sensitive and specific radioimmunoassay. Eur J Biochem 1981;118:339-346
34. MacKenzie CJ, Wakefield JM, Cairns F, Dominiczak AF, Gould GW. Regulation of glucose transport in aortic smooth muscle cells by cAMP and cGMP. Biochem J 2001;353:513-519 (Pubitemid 32158319)
35. Exton JH. Mechanisms of hormonal regulation of hepatic glucose metabolism. Diabetes Metab Rev 1987;3:163-183 (Pubitemid 17002812)
36. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu Rev Biochem 1998;67:821-855
37. Lira VA, Soltow QA, Long JH, Betters JL, Sellman JE, Criswell DS. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab 2007;293:E1062-E1068
38. Zhang J, Xie Z, Dong Y, Wang S, Liu C, Zou MH. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem 2008;283:27452-27461
39. Ramnanan CJ, McMullen DC, Groom AG, Storey KB. The regulation of AMPK signaling in a natural state of profound metabolic rate depression. Mol Cell Biochem 2010;335:91-105
40. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, Hue L, Andreelli F. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006;574:41-53
41. Bergeron R, Previs SF, Cline GW, Perret P, Russell RR 3rd, Young LH, Shulman GI. Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001;50:1076-1082
42. Foretz M, Ancellin N, Andreelli F, Saintillan Y, Grondin P, Kahn A, Thorens B, Vaulont S, Viollet B. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005;54:1331-1339 (Pubitemid 40586661)
43. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, Iglesias MA, Pillot B, Bado A, Tronche F, Mithieux G, Vaulont S, Burcelin R, Viollet B. Liver adenosine monophosphate-activated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006;147:2432-2441
44. Iglesias MA, Ye JM, Frangioudakis G, Saha AK, Tomas E, Ruderman NB, Cooney GJ, Kraegen EW. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51:2886-2894
45. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, Wasserman DH. Portal venous 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion overcomes hyperinsulinemic suppression of endogenous glucose output. Diabetes 2005;54:373-382
46. Pencek RR, Shearer J, Camacho RC, James FD, Lacy DB, Fueger PT, Donahue EP, Snead W, Wasserman DH. 5-Aminoimidazole-4-carboxamide-1-β-D- ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 2005;54:355-360
47. Polekhina G, Gupta A, Michell BJ, van Denderen B, Murthy S, Feil SC, Jennings IG, Campbell DJ, Witters LA, Parker MW, Kemp BE, Stapleton D. AMPK β subunit targets metabolic stress sensing to glycogen. Curr Biol 2003;13:867-871 (Pubitemid 36573256)
48. Mukhtar MH, Payne VA, Arden C, Harbottle A, Khan S, Lange AJ, Agius L. Inhibition of glucokinase translocation by AMP-activated protein kinase is associated with phosphorylation of both GKRP and 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase. Am J Physiol Regul Integr Comp Physiol 2008;294:R766-R774